Synovial sarcoma, X breakpoint 2 (SSX2) (SSX2)

Synovial sarcoma, X breakpoint 2 (SSX2) is a member of the synovial sarcoma X breakpoint family and is classified as a cancer-testis antigen (CTA). In healthy individuals, its expression is primarily restricted to the immune-privileged environment of the testis, but it is aberrantly expressed in a wide range of malignancies, including synovial sarcoma, melanoma, and prostate cancer [2, 6, 9]. In synovial sarcoma, SSX2 is frequently part of the SS18-SSX2 fusion protein resulting from a t(X;18) chromosomal translocation, which acts as an oncoprotein by disrupting chromatin remodeling complexes such as BAF and Polycomb [4, 5, 11]. As a therapeutic target, SSX2 is highly valued for its immunogenicity and tumor-restricted expression profile, making it an ideal candidate for T-cell-based immunotherapies [8, 10, 17]. Current clinical and preclinical strategies include TCR-engineered T cells (TCR-T) and chimeric antigen receptor T cells (CAR-T) that recognize specific SSX2 peptides presented by HLA molecules, as well as cancer vaccines designed to stimulate endogenous anti-tumor immunity [13, 14, 17]. Additionally, small molecule inhibitors targeting the vulnerabilities created by the SS18-SSX fusion, such as ATR or SUMO inhibitors, are being explored to treat synovial sarcoma [11, 12]. The term "SSX2-presenting tumor cells" specifically refers to the cell population expressing this antigen, though the molecular target remains the SSX2 protein or its peptide-MHC complex.

Other names

Cancer/testis antigen 5.2CT5.2HOM-MEL-40SSX family member 2Synovial sarcoma, X breakpoint 2BCancer/testis antigen family 5, member 2a

Immunotherapy (TCR-T and CAR-T cell therapy) targeting SSX2 peptides presented on MHC Class I; Cancer vaccines eliciting SSX2-specific cytotoxic T-lymphocytes; Small molecule inhibition of downstream dependencies (ATR, SUMOylation) or epigenetic induction of antigen expression.